Ascentage Pharma’s Post

With ever increasing costs in new medicine R&D and commercialisation, and further pressures on pricing and market access, pharmaceutical companies need to make sure they are investing in the right opportunities to generate optimal returns.   For core strategic therapy areas, cross-functional team leaders must assess “where to play?” and “how to win?” and balance independent external perspectives with the internal realities of R&D capabilities and existing pipelines.   At Deallus, we have a tried and tested approach for evaluating the relative attractiveness of a group of assets and / or diseases: the Therapy Area Optimisation Solution. This delivers a fully pressure-tested and future-looking strategy, leveraging our deep understanding of the science underlying the main therapy areas and our heritage in competitive intelligence. It ensures alignment on the most relevant set of key parameters that assess the relative opportunity (‘should we’) and the feasibility (‘could we’). Find out more: https://lnkd.in/e-qqpGRq #RandD #opportunity #commercialisation #howtowin #couldwe #shouldwe #investingright

A big year for Bristol Myers Squibb who secured a prominent position in both innovation and invention, maintaining its 5th place in innovation while ascending three places to claim 4th place for invention. BMS experienced a substantial increase in net income despite a minimal decrease in R&D spend in the last year. Additionally, BMS boasted an impressive pipeline-to-portfolio ratio of nearly 400%, showcasing its continued dedication to bringing new treatments to patients. In 2023, BMS achieved several milestones, including 11 approvals in the US, EU, and Japan, 10 Investigational New Drug (IND) applications, and 9 positive readouts in registration and proof-of-concept studies. Notably, the company doubled the number of assets in or entering the registrational stage, reaching a total of 12. The company had over 30 assets in development and the potential for over 40 additional Life Cycle Management (LCM) opportunities across New Molecular Entities (NME) and approved products. See the full analysis here https://lnkd.in/eM35eRGE #pharmaceutical #innovation #PIII2024

drop me a line if you would like to explore how we can support you with a tried and tested process for your therapy area and disease area strategies kevinb@deallus.com!

A growing number of M&A deals in the biotech sector raises key concerns about access to essential medicines and long-term investments in research & development. A few key facts about the biopharma sector: - 420+ M&A Deals in 2023 Q4 - $280+ Billion in M&A Activity in 2023 (1200+ Deals, up 20% from 2022) - Increased Focus on Early-Stage Assets & Pipelines - $250 Million Avg. Deal Size - 50+ Deals Target Anti-Obesity/Weight Loss Medicines in 2023 This trend reflects the industry's ongoing evolution as companies seek to enhance their pipelines, expand their market reach, and leverage new technologies. Read more at healthcarein.org. https://lnkd.in/gvS4CqSV #research #biotech #pharma #medicine #healthcare

Breaking News from Burrard Pharma! I'm thrilled to announce that Burrard Pharmaceuticals has reached a significant agreement with a prominent company in the Middle East to propel technology transfer and expand our Contract Development and Manufacturing Organization (CDMO) production capabilities, particularly in the realm of contrast media. IOHEXOL, a major player in the market, presents immense opportunities for advancement, and we are strategically positioning ourselves to cater to this niche market. With only a few key players in this space, Burrard Pharma's entry marks a pivotal moment in our journey towards innovation and growth. Stay tuned for more details as we embark on this exciting venture! We'll be sharing further insights into how this collaboration will enhance our capabilities and contribute to the healthcare landscape. Burrard Pharma is eager to partner with companies interested in exploring opportunities in this dynamic sector. Together, let's unlock new possibilities in pharmaceutical development and make a meaningful impact on patient care. #BurrardPharma #TechnologyTransfer #CDMO #ContrastMedia #Innovation #HealthcarePartner #iohexol #injection

The November 2023 edition of our #Pharma Services: Drug Development BlueBook is now available! Read why pharma services industry CEOs turn to our BlueBook for valuation trends, strategic activity, and liquidity option insights more than any other publication. November's highlights include: 📌 PhysIQ was acquired by Prolaio 📌 Gauge Capital announced its acquisition of East Coast Institute for Research 📌 Elucid Bioimaging Inc. closed a $80MM Series A Financing, led by Elevage Medical Technologies Download the November edition of the BlueBook: https://hubs.li/Q02dNrM30 #investmentbanking #mergersandacquisitions #pharmaceutical #healthsciences #privateequity

Pharma/Biopharma Executives and leaders are always on a quest to understand where to place the asset “the play” and how to create the winning strategy “the win” for their asset’s commercialisation. Deallus’ Therpay Area Optimisation Solution has been helping create a full proof strategy for delivering success for these objectives. Deallus has been supporting Pharma/Biopharma companies to attain these objectives for over two decades by focusing on key parameters that matter and separating wheat from the chaff. Find out more about our expertise at https://lnkd.in/e-qqpGRq #competitiveintelligence; #brandplanning; #strategy; #managementconsulting; #launchstrategy; #commercialisation; #pharma; #R&D; #lifesciencesconsulting; #biopharma

Things are looking up for the Life Sciences industry as 2023 saw an increase in novel drug #approvals, M&A activity, R&D spending! #Dealmaking activity in 2023 was brighter than expected, with deals worth $163 Bn announced in the year, a staggering 35% growth over 2022. Increased collaboration between Pharma and Tech companies and #growth in Pharmaceutical R&D spending is testament to the industry's focus on #innovation, as they aim to bring about speed, scale and affordability. Healthark Insights' 4th and final report titled "Top 10 Life Sciences Trends of 2023" presents a list of top 10 such trends that have influenced the industry's dynamics in the past year - check out the complete report below! #pharmaceuticalindustry #lifesciencesindustry #lifesciences #markettrends #researchanddevelopment

Тoday, clinical research requires a more comprehensive, strategy-driven delivery with integrated end-to-end solutions. Carefully designed and aligned partnership can guide and optimise the strategic investment of resources and ultimately drive success in drug development programs. Learn more about the changing outsourcing trends between pharma companies and CROs: https://ow.ly/xmIN50QjHne

In our recent poll on Pharma Industry trends for 2024, 𝐎𝐮𝐭𝐬𝐨𝐮𝐫𝐜𝐢𝐧𝐠 𝐭𝐚𝐤𝐞𝐬 𝐭𝐡𝐞 𝐥𝐞𝐚𝐝 𝐰𝐢𝐭𝐡 40% 𝐨𝐟 𝐭𝐡𝐞 𝐯𝐨𝐭𝐞𝐬! 💼💊 #Outsourcing isn't just a trend; it's a strategic move towards #efficiency, #innovation, and #agility. Pharma companies are leveraging external expertise to drive transformative outcomes in drug discovery, clinical trials, and beyond. Exciting times ahead as #collaboration reshapes the future of #healthcare! 💡 For all your pharmaceutical outsourcing needs, connect with Zenvision Pharma LLP today! #PharmaTrends #Outsourcing #Innovation2024 #cdmo